Blackhall, F
110  Ergebnisse:
Personensuche X
?
2

REFINE-Lung implements a novel multi-arm randomised trial d..:

Ghorani, E ; Quartagno, M ; Blackhall, F...
https://discovery.ucl.ac.uk/id/eprint/10169517/3/Quartagno_Refine-lung%20joint%20paper_v9.pdf.  , 2023
 
?
3

ESMO expert consensus statements on the management of EGFR ..:

Passaro, A ; Leighl, N ; Blackhall, F...
info:eu-repo/semantics/altIdentifier/pmid/35176458.  , 2022
 
?
4

Antibiotic use reduces efficacy of tyrosine kinase inhibito..:

Tinsley, N ; Zhou, C ; Nahm, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271482/.  , 2022
 
?
5

Olaparib maintenance versus placebo monotherapy in patients..:

Fennell, D.A ; Porter, C ; Lester, J...
https://eprints.whiterose.ac.uk/195493/1/1-s2.0-S258953702200325X-main.pdf.  , 2022
 
?
6

A local human Vδ1 T cell population is associated with surv..:

Wu, Y ; Biswas, D ; Usaite, I...
https://eprints.whiterose.ac.uk/195647/1/43018_2022_Article_376.pdf.  , 2022
 
?
7

ESMO expert consensus statements on the management of EGFR ..:

Passaro, A ; Leighl, N ; Blackhall, F...
Passaro , A , Leighl , N , Blackhall , F , Popat , S , Kerr , K , Ahn , M J , Arcila , M E , Arrieta , O , Planchard , D , de Marinis , F , Dingemans , A M , Dziadziuszko , R , Faivre-Finn , C , Feldman , J , Felip , E , Curigliano , G , Herbst , R , Jänne , P A , John , T , Mitsudomi , T , Mok , T , Normanno , N , Paz-Ares , L , Ramalingam , S , Sequist , L , Vansteenkiste , J , Wistuba , I I , Wolf , J , Wu , Y L , Yang , S R , Yang , J C H , Yatabe , Y , Pentheroudakis , G & Peters , S 2022 , ' ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer ' , Annals of Oncology , vol. 33 , no. 5 , pp. 466-487 . https://doi.org/10.1016/j.annonc.2022.02.003.  , 2022
 
?
9

A prospective cohort study on the safety of checkpoint inhi..:

Gomes, F ; Lorigan, P ; Woolley, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844568/.  , 2021
 
?
10

Phase I trial of the MEK inhibitor selumetinib in combinati..:

Haslett, K ; Koh, P ; Hudson, A...
Haslett , K , Koh , P , Hudson , A , Ryder , W D , Falk , S , Mullan , D , Taylor , B , Califano , R , Blackhall , F & Faivre-finn , C 2021 , ' Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer ' , Clinical and translational radiation oncology . https://doi.org/10.1016/j.ctro.2021.02.008.  , 2021
 
?
11

A prospective cohort study on the safety of checkpoint inhi..:

Gomes, F ; Lorigan, P ; Woolley, S...
Gomes , F , Lorigan , P , Woolley , S , Foden , P , Burns , K , Yorke , J & Blackhall , F 2021 , ' A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients – the ELDERS study ' , ESMO Open , vol. 6 , no. 1 , 100042 . https://doi.org/10.1016/j.esmoop.2020.100042.  , 2021
 
?
12

Large cell neuroendocrine lung carcinoma: consensus stateme..:

Lindsay, CR ; Shaw, EC ; Moore, DA...
https://discovery.ucl.ac.uk/id/eprint/10135147/1/s41416-021-01407-9.pdf.  , 2021
 
?
13

Is heterogeneity in stage 3 non-small cell lung cancer obsc..:

Hudson, A ; Chan, C ; Woolf, D...
Lung cancer (Amsterdam, Netherlands), 2018, 118 pp. 139 - 147.  , 2020
 
?
14

Vulnerability of drug‐resistant EML4‐ALK rearranged lung ca..:

Paliouras, AR ; Buzzetti, M ; Shi, L...
http://usir.salford.ac.uk/id/eprint/57464/1/emmm.201911099.pdf.  , 2020
 
?
 
1-15